Five Below FIVE
$221.20 −$7.79 (-3.40%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $221.20 0.00%
Open$227.27
Prev close$228.99
Day range$219.12 – $229.68
Volume758.6K
Market cap$12.18B
P/E (TTM)19.8
Dividend yield–
FIVE Stock News
Headlines matching Five Below or the FIVE ticker, most recent first.
- Telsey Advisory Maintains Five Below(FIVE.US) With Buy Rating, Maintains Target Price $305
- Mizuho Securities Maintains Five Below(FIVE.US) With Buy Rating, Raises Target Price to $295 Positive
- A Quick Look at Today's Ratings for Five Below(FIVE.US), With a Forecast Between $295 to $420
- Aim for the water network to cover 82% of the national land area by the end of the 15th Five-Year Plan.
- Meihu Co., Ltd.: Announcement Regarding Penalties or Regulatory Measures Imposed by Securities Regulatory Authorities and Stock Exchanges on the Company Over the Past Five Years
- Netstars: Connecting five major domestic card payment brands to Land. By integrating with a payment platform used by over 5 million companies worldwide, StarPay is expanding its service offerings.
- Yida Co., Ltd.: Announcement Regarding the Absence of Any Penalties or Regulatory Measures Imposed by Securities Regulatory Authorities or Stock Exchanges Over the Past Five Years
- A Quick Look at Today's Ratings for Five Below(FIVE.US), With a Forecast Between $260 to $340
- U.S. job openings fell to a five-month low in August, while layoffs remained subdued. Negative
- Evercore Maintains Five Below(FIVE.US) With Hold Rating, Raises Target Price to $250 Positive
- Zhongda Lide: Announcement by Ningbo Zhongda Lide Intelligent Transmission Co., Ltd. Regarding Regulatory Measures or Penalties Imposed by Securities Regulatory Authorities and Stock Exchanges in the Past Five Years
- Bernstein Upgrades Five Below(FIVE.US) to Buy Rating, Maintains Target Price $272 Positive
- Major Broker Ratings | Citi: The "15th Five-Year" Plan for the pharmaceutical industry is favorable to innovative drugs and medical devices; Hengrui Pharma and Innovent Bio are our top picks, among others.
- Telsey Advisory Maintains Five Below(FIVE.US) With Buy Rating, Maintains Target Price $280
- Apple posts a five-week winning streak: Evercore raised its price target to $380, saying the iPhone upgrade cycle is better than expected. Positive
No comments yet — be the first to weigh in on FIVE.
Sign in to join the discussion.